Date: July 31, 2026

Financial Performance Summary

Anlon Healthcare Limited reported unaudited consolidated financial results for Q1FY27 (quarter ended June 30, 2026) with exceptional growth across all key metrics.

Key Financial Highlights (Consolidated Figures)

| Particulars (₹ Cr) | Q1FY26 | Q1FY27 | Y-o-Y Change |

| Total Income | 33.31 | 87.62 | 163.02% |

| EBITDA | 6.26 | 15.65 | 150.14% |

| PAT | 3.55 | 8.28 | 133.13% |

The company demonstrated strong operational performance with:

  • Total Income growth of 163.02% year-on-year to ₹87.62 crore
  • EBITDA growth of 150.14% year-on-year to ₹15.65 crore
  • Profit After Tax growth of 133.13% year-on-year to ₹8.28 crore

Strategic Developments During Q1FY27

Acquisition and Expansion

  • Acquired 63.98% stake in Remember India Health Links Pvt. Ltd. for ₹5.38 crore
  • Transaction completed on May 8, 2026, making Remember India Health Links a subsidiary
  • Strategic entry into Finished Dosage Formulations (FDF) segment
  • Access to 30+ formulation dossiers for tablets, capsules and other pharmaceutical formulations

Business Expansion

  • Expanded across pharmaceutical value chain from API to formulations
  • Enhanced market presence in B2B APIs, domestic retail and hospital markets
  • Improved operational synergies through integration of manufacturing and quality control processes
  • Strengthened long-term scalability through operational efficiencies

Management Commentary

Mr. Punitkumar Rasadia, Chairman & Managing Director, commented on the results:

  • Commenced FY27 with strong performance reflecting diversified pharmaceutical portfolio and customer confidence
  • Healthy margins demonstrate resilience of business model and focus on operational excellence
  • Acquisition of Remember India Health Links marks strategic entry into FDF segment
  • Strategic investments with Apiqo Organics and Bizotic Lifescience enhance manufacturing capabilities and broaden product portfolio
  • Creating meaningful operational synergies across pharmaceutical value chain

Future Outlook and Guidance

  • Focus on expanding presence in regulated markets
  • Scaling CDMO business
  • Leveraging integrated pharmaceutical platform for sustainable growth
  • Long-term guidance of approximately 30% revenue CAGR over next three years
  • Target to maintain EBITDA margins in range of 25%–30%

Corporate Background

  • Incorporated in 2013, headquartered in Rajkot, Gujarat
  • Research-driven pharmaceutical company manufacturing high-purity pharmaceutical intermediates and APIs
  • Expanding into Finished Dosage Formulations through strategic acquisitions
  • Serves pharmaceutical, nutraceutical, personal care and animal health industries across 15+ countries
  • Key API products: Loxoprofen Sodium Dihydrate, Ketoprofen, Dexketoprofen Trometamol (pain and inflammation management)
  • Installed capacity: 1,400-1,600 MTPA
  • Four R&D centers
  • Global presence across 15+ countries